Clinical Trial Update: Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

View source ↗

Summary

Prospective post-marketing surveillance study of cetuximab (Erbitux) in Korean patients with locally advanced, recurrent, or metastatic squamous cell carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Head and Neck Cancer | Status: COMPLETED